Chondroitin sulphate: a focus on osteoarthritis

详细信息    查看全文

• 作者：Mamta Bishnoi ; Ankit Jain ; Pooja Hurkat ; Sanjay K. Jain
• 关键词：Chondroitin sulfate ; Osteoarthritis ; Glucosamine ; Glycosaminoglycanes ; Anti ; inflammatory ; Targeting ; Drug delivery
• 刊名：Glycoconjugate Journal
• 出版年：2016
• 出版时间：October 2016
• 年：2016
• 卷：33
• 期：5
• 页码：693-705
• 全文大小：998 KB
• 刊物类别：Biomedical and Life Sciences
• 刊物主题：Life Sciences
  Biochemistry
  Pathology
  
• 出版者：Springer Netherlands
• ISSN：1573-4986
• 卷排序：33

文摘

Chondroitin sulfate (CS) being a natural glycosaminoglycan is found in the cartilage and extracellular matrix. It shows clinical benefits in symptomatic osteoarthritis (OA) of the finger, knee, hip joints, low back, facial joints and other diseases due to its anti-inflammatory activity. It also helps in OA by providing resistance to compression, maintaining the structural integrity, homeostasis, slows breakdown and reduces pain in sore muscles. It is most often used in combination with glucosamine to treat OA. CS is a key role player in the regulation of cell development, cell adhesion, proliferation, and differentiation. Its commercial applications have been continuously explored in the engineering of biological tissues and its combination with other biopolymers to formulate scaffolds which promote and accelerate the regeneration of damaged structure. It is approved in the USA as a dietary supplement for OA, while it is used as a symptomatic slow-acting drug (SYSADOA) in Europe and some other countries. Any significant side effects or overdoses of CS have not been reported in clinical trials suggesting its long-term safety. This review highlights the potential of CS, either alone or in combination with other drugs, to attract the scientists engaged in OA treatment and management across the world.